Article

Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes

  • Nature Microbiology 1, Article number: 16087 (2016)
  • doi:10.1038/nmicrobiol.2016.87
  • Download Citation
Received:
Accepted:
Published online:

Abstract

The arbovirus life cycle involves viral transfer between a vertebrate host and an arthropod vector, and acquisition of virus from an infected mammalian host by a vector is an essential step in this process. Here, we report that flavivirus nonstructural protein-1 (NS1), which is abundantly secreted into the serum of an infected host, plays a critical role in flavivirus acquisition by mosquitoes. The presence of dengue virus (DENV) and Japanese encephalitis virus NS1s in the blood of infected interferon-α and γ receptor-deficient mice (AG6) facilitated virus acquisition by their native mosquito vectors because the protein enabled the virus to overcome the immune barrier of the mosquito midgut. Active immunization of AG6 mice with a modified DENV NS1 reduced DENV acquisition by mosquitoes and protected mice against a lethal DENV challenge, suggesting that immunization with NS1 could reduce the number of virus-carrying mosquitoes as well as the incidence of flaviviral diseases. Our study demonstrates that flaviviruses utilize NS1 proteins produced during their vertebrate phases to enhance their acquisition by vectors, which might be a result of flavivirus evolution to adapt to multiple host environments.

  • Subscribe to Nature Microbiology for full access:

    $59

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    & Pathogenic flaviviruses. Lancet 371, 500–509 (2008).

  2. 2.

    et al. Dengue and dengue haemorrhagic fever. Lancet 352, 971–977 (1998).

  3. 3.

    et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).

  4. 4.

    et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89, 766–774 (2011).

  5. 5.

    & The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 98, 192–208 (2013).

  6. 6.

    et al. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science 343, 881–885 (2014).

  7. 7.

    , , & An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J. Clin. Microbiol. 38, 1053–1057 (2000).

  8. 8.

    et al. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J. Clin. Microbiol. 40, 376–381 (2002).

  9. 9.

    et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci. Transl. Med. 7, 304ra141 (2015).

  10. 10.

    et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci. Transl. Med. 7, 304ra142 (2015).

  11. 11.

    et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 207, 793–806 (2010).

  12. 12.

    , & Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1. J. Gen. Virol. 68, 853–857 (1987).

  13. 13.

    et al. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J. Immunol. 174, 395–403 (2005).

  14. 14.

    , , & Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J. Biol. Chem. 286, 9726–9736 (2011).

  15. 15.

    et al. A highly conserved region between amino acids 221 and 266 of dengue virus non-structural protein 1 is a major epitope region in infected patients. Am. J. Trop. Med. Hyg. 91, 146–155 (2014).

  16. 16.

    et al. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol. Immunol. 47, 398–406 (2009).

  17. 17.

    et al. Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention. PLoS Pathogens 10, e1003931 (2014).

  18. 18.

    , , & Mosquito defense strategies against viral infection. Trends Parasitol. 32, 177–186 (2016).

  19. 19.

    & Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. J. Med. Virol. 80, 547–556 (2008).

  20. 20.

    et al. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4, e672 (2010).

  21. 21.

    et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J. Gen. Virol. 93, 2152–2157 (2012).

  22. 22.

    Dengue. Lancet 370, 1644–1652 (2007).

  23. 23.

    et al. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for DEN2-43 and New Guinea C virus strains of dengue 2 virus. Acta Trop. 128, 566–570 (2013).

  24. 24.

    et al. Predicting unprecedented dengue outbreak using imported cases and climatic factors in Guangzhou, 2014. PLoS Negl. Trop. Dis. 9, e0003808 (2015).

  25. 25.

    et al. NS1′ protein expression facilitates production of Japanese encephalitis virus in avian cells and embryonated chicken eggs. J. Gen. Virol. 95, 373–383 (2014).

  26. 26.

    , & The Aedes aegypti toll pathway controls dengue virus infection. PLoS Pathogens 4, e1000098 (2008).

  27. 27.

    et al. Dengue virus type 2 infections of Aedes aegypti are modulated by the mosquito's RNA interference pathway. PLoS Pathogens 5, e1000299 (2009).

  28. 28.

    , & An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense. Proc. Natl Acad. Sci. USA 106, 17841–17846 (2009).

  29. 29.

    et al. Antiviral immunity of Anopheles gambiae is highly compartmentalized, with distinct roles for RNA interference and gut microbiota. Proc. Natl Acad. Sci. USA 112, E176–E185 (2015).

  30. 30.

    et al. Natural microbe-mediated refractoriness to Plasmodium infection in Anopheles gambiae. Science 332, 855–858 (2011).

  31. 31.

    et al. Bacterial-derived uracil as a modulator of mucosal immunity and gut–microbe homeostasis in Drosophila. Cell 153, 797–811 (2013).

  32. 32.

    et al. The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of Drosophila. Nature Immunol. 6, 946–953 (2005).

  33. 33.

    The malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 8, e1000398 (2011).

  34. 34.

    The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch. Virol. 142, 897–916 (1997).

  35. 35.

    , , & Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87, 339–346 (2006).

  36. 36.

    et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 30, 837–845 (2012).

  37. 37.

    et al. Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito Aedes aegypti. Proc. Natl Acad. Sci. USA 109, E23–E31 (2012).

  38. 38.

    et al. A C-type lectin collaborates with a CD45 phosphatase homolog to facilitate West Nile virus infection of mosquitoes. Cell 142, 714–725 (2010).

  39. 39.

    et al. Dengue virus infection of Aedes aegypti requires a putative cysteine rich venom protein. PLoS Pathogens 11, e1005202 (2015).

  40. 40.

    et al. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malaria J. 6, 107 (2007).

  41. 41.

    , , & A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS ONE 4, e6352 (2009).

  42. 42.

    et al. Antiviral peptides targeting the West Nile virus envelope protein. J. Virol. 81, 2047–2055 (2007).

  43. 43.

    & Immunoaffinity purification of the native dimer forms of the flavivirus non-structural protein, NS1. J. Virol. Methods 30, 323–332 (1990).

  44. 44.

    Large-scale preparation and concentration of retrovirus stocks. Curr. Protoc. Mol. Biol. 9, 9.12.1–9.12.6 (2001).

  45. 45.

    , & Basic Medical Laboratory Techniques Ch. 2 (Cengage Learning, 2000).

  46. 46.

    Isolation of human platelets (thrombocytes). Sci. World J. 2, 1607–1609 (2002).

Download references

Acknowledgements

This work was funded by grants from the National Natural Science Foundation of China (81301412, 81422028 and 81571975), National Program on Key Research Project of China (Prevention of livestock and poultry diseases and development of comprehensive farming technology), the National Key Basic Research Program of MOST (2013CB911500), Grand Challenges Explorations of the Bill & Melinda Gates Foundation (OPP1021992) and the National Institutes of Health of the USA (AI103807). The authors thank S. B. Halstead for providing critical suggestions for the manuscript. G.C. is a Newton Advanced Fellow (awarded by the Academy of Medical Sciences and the Newton Fund). G.C. is also a Janssen Investigator at Tsinghua University. The authors acknowledge the core facilities of the Center for Life Sciences and Center of Biomedical Analysis for technical assistance (Tsinghua University).

Author information

Author notes

    • Jianying Liu
    •  & Yang Liu

    These authors contributed equally to this work.

Affiliations

  1. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Medicine, Tsinghua University, Beijing 100084, China

    • Jianying Liu
    • , Yang Liu
    • , Kaixiao Nie
    • , Senyan Du
    • , Xiaojing Pang
    •  & Gong Cheng
  2. SZCDC-SUSTech Joint Key Laboratory for Tropical Diseases, Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong 518055, China

    • Yang Liu
    •  & Gong Cheng
  3. School of Life Science, Tsinghua University, Beijing 100084, China

    • Yang Liu
  4. Department of Health Statistics, School of Preventive Medicine, Fourth Military Medical University, Shaanxi 710032, China

    • Jingjun Qiu
  5. Department of Microbiology and Immunology, School of Medicine, New York Medical College, Valhalla, New York 10595, USA

    • Penghua Wang

Authors

  1. Search for Jianying Liu in:

  2. Search for Yang Liu in:

  3. Search for Kaixiao Nie in:

  4. Search for Senyan Du in:

  5. Search for Jingjun Qiu in:

  6. Search for Xiaojing Pang in:

  7. Search for Penghua Wang in:

  8. Search for Gong Cheng in:

Contributions

G.C. designed the experiments and wrote the manuscript. Y.L. and J.L. performed the majority of the experiments and analysed data. K.N., S.D. and X.P. helped with RNA isolation and qPCR detection. J.Q. assisted in the statistical analysis. P.W. contributed experimental suggestions and improved the writing of the manuscript. All authors reviewed, critiqued and provided comments on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Gong Cheng.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Figures 1-11, Supplementary Tables 1 and 2.